This article reviews key methodological considerations for clinical trials that utilize explanatory and pragmatic trial designs and relates these contrasting approaches to the interpretation of results from comparisons of oral versus long-acting injectable (LAI) antipsychotics in schizophrenia. Explanatory randomized controlled trials (RCTs) generally measure the efficacy of a treatment in a homogeneous population with intensive, frequent, and often clinical trial-specific assessments. In contrast, pragmatic trials measure effectiveness in routine clinical practice and frequently aim to inform choices between treatments. Comparative effectiveness outcomes with pragmatic designs in naturalistic settings for schizophrenia treatments are of increasing interest to healthcare providers because outcomes of treatment (both efficacy and safety) may vary significantly when identified in an explanatory setting compared with a naturalistic pragmatic setting. Indeed, it has been suggested that the inconsistent outcomes observed in trials comparing oral and LAI antipsychotic medications may be a function of the use of explanatory or pragmatic trial designs. In practice, clinical trial designs are seldom purely explanatory or pragmatic. To identify the predominant orientation of a trial, one must consider multiple features. This paper reviews the relative impact of these features when comparing LAI and oral antipsychotic treatments and makes recommendations for improving these comparative designs.
Introduction
The question of whether long-acting injectable (LAI) antipsychotics offer meaningful advantages over oral antipsychotics in the treatment of individuals with schizophrenia has been addressed in recent studies with inconsistent results (Chue et al., 2005; Bai et al., 2006; Emsley et al., 2008; Weiden et al., 2009; Gaebel et al., 2010; Macfadden et al., 2010; Rosenheck et al., 2011; Schooler et al., 2011; Weiden et al., 2012; Zhornitsky and Stip 2012; Barrio et al., 2013) . Meta-analytical reviews of these studies have been similarly inconsistent (Leucht et al., 2011; Fusar-Poli et al., 2013; Kirson et al., 2013; Kishimoto et al., 2013 Kishimoto et al., , 2014 . Consequently, whether treatment with oral or LAI formulations of antipsychotics produces meaningfully different outcomes remains a matter of debate.
Pharmacological differences are unlikely to explain potential differences in treatment outcomes between LAI and oral formulations because the medications in both groups have similar (Weiden et al., 2009; Gaebel et al., 2010; Macfadden et al., 2010; Schooler et al., 2011; Weiden et al., 2012; Zhornitsky and Stip 2012; Barrio et al., 2013) , sometimes identical (Chue et al., 2005; Bai et al., 2006; Emsley et al., 2008) , pharmacological mechanisms. Rather, potential differences in effectiveness between LAI and oral antipsychotics are most likely attributable to the fact that, in clinical practice, administration of an LAI guarantees medication adherence during the postinjection treatment interval. In addition, failure to receive a follow-up injection signals the onset of nonadherence. In contrast, adherence to oral treatment is nearly always uncertain.
Explanatory randomized controlled trials (RCTs) of pharmacological treatments are designed to study the efficacy and safety of molecules under well-controlled circumstances. Subjects selected must understand and consent to both treatment and assessment procedures and are expected to adhere to the protocol. Further, a great deal of attention is paid to ensuring and reinforcing protocol compliance. Such care may preclude detection of differences between LAI and oral medication formulations that are present in actual practice. Pragmatic studies, in which differences in adherence are less constrained, seem more likely to mirror real-world practice and may offer advantages.
The aims of this article are (1) to review in detail differences between explanatory and pragmatic trial designs, (2) to show how these design considerations may impact interpretation of disparate findings from studies that have compared LAIs versus oral medications, and (3) to offer recommendations for such studies going forward.
Design considerations

Specification of study objectives
Studies designed to address one objective may not be appropriate for addressing others, even if the objectives are related. Indeed, if an inappropriate study design is selected, results may be misleading. The specific study objective and design characteristics must be aligned (American Psychological Association, 2010) .
Careful definition of the study objective is particularly critical when one is looking for potential treatment differences between oral and LAI antipsychotic medications. First, it must be determined if the study focus is to ascertain whether the medication is inherently effective and safe, or whether the medication is effective and safe in naturalistic practice settings (i.e., whether a more explanatory or a more pragmatic design is needed [Section 2.2]). Then, the trial design must be selected according to whether the study is to show equivalence, non-inferiority, or superiority over the comparator treatment. Each approach requires a very different study design and analytical method.
Pragmatic versus explanatory design
Explanatory clinical trials generally measure efficacy of a treatment in a relatively homogeneous population by performing intensive, frequent, and standardized clinical assessments, whereas pragmatic trials measure effectiveness in more heterogeneous populations in routine clinical practice. Actual clinical trial designs represent a spectrum of pragmatic and explanatory approaches; seldom is a trial purely explanatory or purely pragmatic (Thorpe et al., 2009) . Several study design domains are particularly relevant for characterizing a study along the pragmatic-explanatory continuum. These include design choices around (1) patient population selection; (2) site selection and medical practice setting/practitioner expertise found at the site; (3) degree of intervention flexibility allowed during the evaluation; (4) measures of primary and secondary trial outcomes; (5) participant adherence to treatment and to assessment; and (6) whether subjects are randomly assigned to treatment (Table 1) .
2.3. Specific study design features relevant to pragmatic-explanatory continuum 2.3.1. Patient population selection A key consideration in study design involves the definition of the population to be studied. Explanatory clinical trials designed to demonstrate intrinsic efficacy and safety of a treatment seldom randomly sample from the total population of potential patients with the illness that needs to be treated. Indeed, to minimize interpretive confounds from concomitant medications and comorbid conditions, restrictive selection criteria for potential subjects often identify constrained population subgroups for study. Most studies further select subjects who are likely to be adherent with treatment and trial procedures by excluding patients with a history of noncompliance or substance abuse (Thorpe et al., 2009) . Additionally, patients enrolled in clinical trials are more likely to adhere to treatment regimens when they are aware that their compliance is being strictly monitored. This is specifically seen in schizophrenia trials (Gutiérrez-Casares et al., 2010; Kirson et al., 2013) . Other exclusion criteria in trials investigating the treatment of schizophrenia frequently eliminate participants at highest risk of unfavorable outcomes (treatment resistant) and those with psychiatric and medical conditions that might interfere with assessment of the safety and efficacy of the treatment(s) being evaluated (Bai et al., 2006; Fleischhacker et al., 2012) . Although this process is useful in selecting subjects for whom observed efficacy and safety data are most clearly attributable to the study drug, it is unlikely to yield a sample population that is fully representative of patients who will be treated in real-world clinical practice settings.
Pragmatic trials strive to enroll all patients who meet the basic entry criteria for the population of interest defined by the study question (i.e., ideally, no additional restrictions are applied to the predefined population of interest). Thus, with perfect pragmatic designs of adequate size, considerations such as responsiveness, adverse events, and treatment adherence should be fully reflective of the population identified by the study question/hypothesis. However, even prospective trials that aim to be pragmatic are constrained by sample size and selection biases arising from the need for informed consent, the range of patients available at the study site, and the selection biases that draw patients to that site. For example, in comparing LAIs to oral treatments, patient reluctance to receive injections can reduce the likelihood that such patients will enroll in the trials and increase dropout, thus altering the representativeness of the trial population (Kishimoto et al., 2013 (Kishimoto et al., , 2014 . These selection issues represent limitations for nearly all pragmatic clinical trials. Nevertheless, despite their imperfections, wellconducted pragmatic trials better reflect the broad range of patients found in regular clinical practice, and results of pragmatic trials will be more broadly generalizable than those from explanatory trials.
When data from schizophrenia trials comparing LAI and oral treatment outcomes are compared, additional patient characteristics are relevant. These include severity and stability of symptoms, duration of follow-up, and clinical history such as duration of illness and number of prior relapses/hospitalizations. For example, differences in efficacy between LAI and oral treatments may be more evident in recently diagnosed patients, perhaps because they are less likely to be adherent to treatment than more chronically ill patients (Subotnik et al., 2012) . Attitudes toward taking medicine and, by implication, adherence to treatment may be affected by local culture, ethnicity, age, and gender and may affect relative treatment response.
Site selection and medical practice setting/practitioner expertise
The representativeness of the skill sets of practitioners and the characteristics of the clinical settings relative to those in which the treatment will be applied also affect the degree to which a trial is explanatory or pragmatic. Local standards of clinical practice, the skill and experience of practitioners, and the availability of concomitant or alternative treatment options may affect treatment outcomes. In explanatory trials, experienced practitioners in optimal clinical settings are usually most desirable. On the other hand, a prototypic pragmatic study selects broadly, although rarely randomly, from the range of relevant clinical practices the settings in which treatment is to be given. Treatment settings and practices also change over time. This is relevant when the results of both explanatory and pragmatic trials that have been completed across an extensive time span are evaluated in meta-analyses. Meta-analyses that compare LAI antipsychotics versus oral medications may be confounded by differences in treatment practice that may have been prevalent when alternative treatment options were prevalent. For explanatory and most prospective pragmatic trials, a standardized protocol and systematic training are used to reduce variability in assessment and experience. However, adherence to these study-specific standards and training reduces their pragmatic character.
To assess the generalizability of clinical trial results with LAI versus oral antipsychotics, it is necessary to understand (1) the heterogeneity of schizophrenia, (2) the varieties of clinical practice applied to schizophrenia throughout the world, and (3) how well both of these have been sampled in the clinical trial.
Intervention flexibility during evaluation
Explanatory trials generally constrain intervention flexibility to ensure that information truly reflects the intrinsic efficacy and safety of the drug at the specific doses or dose ranges being evaluated. Conversely, interventions in the most pragmatic trials are highly flexible so as to reflect real-world practice and allow for broad decision making by the clinician. In prospective, randomized pragmatic trials, subjects may be allowed to stop, adjust dose, or switch from their randomly assigned treatment to improve efficacy and tolerability (Macfadden et al., 2010) . However, the documentation of these practices required for prospective clinical trials is likely to reduce the pragmatic characteristics of the trial and may affect the outcome.
Choice of primary and secondary trial outcomes
In explanatory trials, the primary outcome measure usually addresses short-term consequences of the intervention. The measures most commonly used are specific symptoms that may not reflect functional improvement. A 6-point change on a rating scale, such as the Young Mania Rating Scale (Turkoz et al., 2013) , is not an intuitively meaningful value for the practicing clinician, and it may not be correlated with functional improvement. Pragmatic trials, on the other hand, generally include primary outcome measures that are objectively measured and intuitively meaningful to most stakeholders, including the patient and public health officials. In the comparison between LAIs and oral medications for schizophrenia, these can include such outcomes as hospitalization rates (Grimaldi-Bensouda et al., 2012) or time to relapse (Macfadden et al., 2010) .
Because explanatory trials focus on the efficacy and safety of a particular treatment, outcomes are defined by change in a measure or time to a specified symptomatic change during randomized treatment. Information on the subject's actual condition at a predefined endpoint in time is usually not required. With such designs, the treatment may have been discontinued before a predefined follow-up period was completed. In contrast, pragmatic trials aim to measure functionally important outcomes after a prespecified time interval, regardless of whether randomized treatment is ongoing or discontinued. The best pragmatic studies follow all subjects for the predefined interval, regardless of whether they remain on the assigned treatment. Explanatory trials seldom have this continued follow-up, and because of early dropouts, outcome information for a constant follow-up interval must often be imputed. Imputation of outcomes measured before the defined endpoint is highly problematic, as it is associated with censoring biases. Because events that occur after early discontinuation may be extremely relevant to the patient's predefined outcome, great pains must be taken to follow all patients in these studies, even if the assigned primary treatment has been discontinued. Head-to-head pragmatic trials that allow switching of medications to the alternative study treatment, as is sometimes done in comparisons of LAI and oral antipsychotic treatments, can raise fundamental conundrums regarding appropriate attribution of safety and efficacy outcomes, as, after the point of switch, they may be a consequence of study treatments or their interaction. In such instances, this can be addressed only partially by censoring data at the point of switch to the alternative therapy.
"Relapse" or "time-to-relapse" is frequently used as an explanatory endpoint in schizophrenia trials. However, "relapse" is a challenging pragmatic endpoint for several reasons. First, no universal definition of "relapse" is available; sometimes it is equated with hospitalization, but drivers of hospitalization differ by treatment system and change over time. Also, "relapse" does not address potentially greater efforts to maintain stability with one treatment rather than another (e.g., in terms of clinical care with oral antipsychotics rather than LAIs). Further, "relapse" is unidimensional and, even in that dimension, does not adequately encompass the various levels of outcome that are short of full relapse (i.e., relapse rates may not differ, but patients in one group may be symptomatically improved and have better long-term outcomes or may experience a better quality of life). Clinicians, patients, and payers are often interested in a summation of overall outcome over a defined time frame rather than simply the occurrence of a single event. Other stakeholders (like payers) may be interested in highimpact events but would want to know their cumulative impact over a defined time frame for each subject, not just the occurrence of an event at a single point in time or the time to the first event. This is not to say that "relapse" cannot be a useful outcome measure; rather, that it must be well defined and should be used in combination with other validated outcomes that include a spectrum of positive as well as negative outcome responses. Future trials could further define the relapse continuum by including other measures such as improvements from baseline, exacerbations not leading to relapse, duration of remission of symptoms (psychoses, negative symptoms, etc.), maintenance of stability, and/or maintenance of reductions in violent behavior and in incarceration/arrest/recidivism.
Participant adherence to treatment and to assessment
As has already been discussed, nonadherence must be minimized in explanatory trials to permit determination of whether results truly pertain to the efficacy and safety of the treatments under consideration. However, nonadherence should be allowed in pragmatic trials, as this reflects a very relevant clinical outcome. In pragmatic trials, assessment burden and requirements for maintaining treatment adherence should attempt to reflect actual practice for treatment adherence to the treatments under study. Thus, in pragmatic studies comparing LAI and oral medications, visit frequency may well vary between treatment groups. This better reflects a real-world clinical situation in which the interval between clinic visits will be determined by the injection interval in patients receiving LAI medications; visit frequency for those receiving oral antipsychotics may vary substantially, being as infrequent as once every 3 months or as frequent as once weekly. Clinic visits and delivery of an injection allow a definitive assessment of adherence to LAI medications, but adherence to oral treatments can only be determined by less definitive methods. These include self report, pharmacy data, clinical records, family report, pill counts (manual or electronic), or serum medication levels (Valenstein et al., 2002; Weiden et al., 2009; Rosenheck et al., 2011) .
Superiority versus noninferiority versus equivalence
Another important aspect of clinical trial design involves whether the investigation is to be a superiority, a noninferiority, or an equivalence trial. Both explanatory and pragmatic trials can be designed to assess superiority, noninferiority, or equivalence, but these reflect fundamentally different approaches to trial design that entail consideration of study population, endpoints, duration, and management of bias.
Both noninferiority and equivalence trials require the explicit identification of clinically justified margins and usually require a larger sample size than that required for superiority trials that use null hypothesis testing. This can be particularly problematic in trials of schizophrenia treatments in which recruitment challenges and high dropout rates make recruitment and retention for follow-up difficult (Jørgensen et al., 2014) . Retention is particularly important for pragmatic trials where the point of drop out may be the point of greatest interest.
Further, identifying a superiority margin goes beyond rejection of the null hypothesis and allows a statement that the difference detected is meaningful from a clinical or public health perspective. The superiority margin generally represents a public health perspective rather than an individual patient's perspective, but it should be justified. Failure to achieve superiority does not represent noninferiority unless a predefined noninferiority margin has also been met. Rejection of the null hypothesis does not mean that the two treatments are equivalent. The literature is often unclear about this: Describing trials that have failed to reject a null hypothesis as showing that treatments are equivalent is not uncommon. On the other hand, identification of superiority in a noninferiority trial may be clinically relevant if a superiority margin has been predefined.
Randomization
Explanatory clinical trials always involve random assignment to treatment. Pragmatic trials may incorporate randomization, but randomization compromises the degree to which the trial reflects naturalistic treatment. Nonrandomized pragmatic trials are also an option, but such studies introduce limitations related to selection bias. These biases should be explicitly noted in the interpretation and may be addressed by the use of techniques such as propensity matching (Rosenbaum and Rubin, 1983; Austin, 2011) .
The act of randomization itself may bias results in terms of both patient and site selection with consequences for generalizability of the results. Patients who consent to participate in randomized controlled trials at sites that conduct them are willing to be involved with a more formalized type of care than is standard. A patient who is willing to participate in such a study has self-identified at several levels as someone who (1) needs medical care; (2) is willing to take treatment; and (3) is willing to have treatment assigned randomly rather than by choice. Such patients may be more likely to be adherent to medication than those not willing to participate in randomized trials, although to our knowledge, no one has ever formally addressed this question. Clinical sites that conduct randomized studies may be selected on the basis of increased skill sets of the practitioners, their ability to provide more frequent and intense treatment, their attitudes toward that treatment, and their ability to provide support to patients who consent to random assignment to treatment.
Randomization is the explanatory feature that most often characterizes trials that seek to bridge the pragmatic-explanatory continuum. This approach incorporates a major strength of explanatory designs but does introduce the limitations noted above.
The explanatory-pragmatic continuum
Many studies incorporate both explanatory and pragmatic elements. Such an approach is helpful to researchers who seek to gain insight into complicated clinical questions, but recognition of the characteristics of the trial is important, as these limit interpretation of the results (Tosh et al., 2011; Bossie and Alphs 2013) . For example, because explanatory approaches usually put constraints on visit frequency and the content of those visits, such that they may alter adherence, results from comparisons of oral and LAI antipsychotics may be dependent on whether this explanatory feature is incorporated into the trial.
Recommendations
In the design, review, and interpretation of clinical trials, the primary questions for a study and for the stakeholders are critical considerations. If the question being addressed concerns the safety and efficacy attributes of a particular treatment, the design should be more explanatory. If the question concerns how safe and effective the treatment is in naturalistic clinical practice, the design should be more pragmatic. It is important to recognize that whatever approach is taken, any particular clinical trial will have limitations, and multiple studies are necessary if one is to gain complete understanding of the safety, efficacy, and role in clinical practice of a novel treatment. Examination of study approaches used when oral and LAI antipsychotic treatments are compared is particularly critical, as outcomes may be strongly influenced by design decisions. Table 2 summarizes the steps that can be taken to increase the pragmatism of studies that compare oral versus Table 2 Recommendations for increasing pragmatism in clinical trials of schizophrenia comparing oral and LAI antipsychotic treatment response.
Trial parameter
Recommendation(s)
Treatment schedules ▪ Use treatment schedules that mirror real-world contact with doctors and nurses as seen in naturalistic practice (i.e., LAI arm: 2 weekly to 1 monthly; oral arm: 1 to 3 monthly, depending on symptoms and local practice)
• Treatment personnel seen by the patient should model those seen in standard practice. For instance, LAI patients may receive injections from a nurse and may not see a physician or nurse/practitioner at every visit Blinding ▪ Avoid double-blind trials in which all subjects receive injections and tablets (double-dummy designs) because they do not reflect clinical practice and therefore may lead to unrepresentative results Adherence and treatment compliance ▪ During clinic visits, staff should use adherence-advancing interventions as they normally would during customary practice Trial duration ▪ Ideally, duration of follow-up should be at least 1 year; however, if the goal is to detect outcomes beyond relapse, the trial may be longer ▪ Caveat: Longer trials have greater potential for incomplete follow-up with possible regression to the mean, dependent variable censoring, and consequent loss of sensitivity to actual treatment response Dropouts ▪ Diligence to avoid dropouts is critical, as they are a significant source of bias; the point of dropout is perhaps the point at which greatest differentiation begins ▪ Strategies to reduce dropouts could include conducting the trial in the context of an outcome tracking system that is independent of the primary study (e.g., Medicaid, Veterans Affairs). This may, however, introduce other selection biases LAI antipsychotic treatment response in patients with schizophrenia or similar psychotic disorders. Reports of such studies should incorporate discussion of the degree to which they incorporated explanatory and pragmatic characteristics and how these influence interpretation of results.
Conclusions
Once basic questions of safety and efficacy have been addressed, stakeholders such as healthcare providers and payers increasingly desire information about comparative outcomes with pragmatic designs. Pragmatic studies (sometimes called effectiveness research) have unique characteristics that differ from those of more familiar explanatory trials. These distinctions are particularly critical in evaluating outcomes from studies comparing LAIs versus oral antipsychotic treatments when pragmatic or explanatory design features may fundamentally affect observed outcomes.
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